Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: A retrospective multicenter analysis

Wspolczesna Onkologia

Volumn 17, Issue 3, 2013, Pages 257-262

  Wiater, Katarzyna ^a   Witaj, Tomasz ^a   Mackiewicz, Jacek ^b,c,d   Kalinka Warzocha, Ewa ^e   Wojtukiewicz, Marek ^f   Szambora, Pawe ^f   Falkowski, Sawomir ^a   Rogowski, Wojciech ^g   Mackiewicz, Andrzej ^b,c   Rutkowski, Piotr ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c GREATER POLAND CANCER CENTRE   (Poland)

^d Malgorzata Medical Center   (Poland)

^e Regional Cancer Center   (Poland)

^f MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^g Warmia and Masuria Oncology Center   (Poland)

Author keywords

CTLA 4; Immunotherapy; Ipilimumab; Melanoma; Outcome

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB;

ADULT; AGE DISTRIBUTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASTHENIA; AUTOIMMUNE THYROIDITIS; CANCER STAGING; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; CUTANEOUS MELANOMA; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; ENDOCRINE DISEASE; FEBRILE NEUTROPENIA; FEMALE; HEALTH CARE ACCESS; HEALTH PROGRAM; HEPATITIS; HUMAN; HYPERTHYROIDISM; HYPOPHYSITIS; HYPOTHYROIDISM; LYMPHOCYTIC HYPOPHYSITIS; MALE; METASTATIC MELANOMA; MULTICENTER STUDY; NEUTROPENIA; OVERALL SURVIVAL; PRIMARY OCULAR MELANOMA; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; RETROSPECTIVE STUDY; SEX RATIO; SIDE EFFECT; THYROID CRISIS; TREATMENT FAILURE; TREATMENT RESPONSE; VITILIGO;

EID: 84880074776     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2013.35785     Document Type: Article

References (27)

1. O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 2007; 110: 2614-27.
2. Eggermont AM, Robert C. New drugs in melanoma: It's a whole new world. Eur J Cancer 2011; 47: 2150-7.
3. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271: 1734-6.
4. Wolchok JD, Hoos A, O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412-0.
5. Switaj T, Wysocki P, Wojtukiewicz M, et al. Ipilimumab-Progress in therapy of advanced melanoma. Onkol Prakt Klin 2011; 7: 231-45.
6. Kähler KC, Hauschild A. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma. J Dtsch Dermatol Ges 2011; 9: 277-85.
7. Kaehler KC, Piel S, Livingstone E, Schilling B, Hauschild A, Schadendorf D. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol 2010; 37: 485-98.
8. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-206.
9. Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000; 19: 21-34.
10. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
11. Prieto PA, Yang JC, Sherry RM et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012; 18: 2039-47.
12. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-26.
13. O'Day SJ, Maio M, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: amulticenter single-arm phase II study. Ann Oncol 2010; 21: 1712-7.
14. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009; 15: 5591-8.
15. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11: 155-64.
16. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012; 13: 459-65.
17. Ku GY, Yuan J, Page DB, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 2010; 116: 1767-75.
18. Carthon BC, Wolchok JD, Yuan J, et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 2010; 16: 2861-71.
19. Fu T, He Q, Sharma P. The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res 2011; 71: 5445-54.
20. Danielli R, Ridolfi R, Chiarion-Sileni V, et al. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunol Immunother 2012; 61: 41-8.
21. Khattak MA, Fisher R, Hughes P, Gore M, Larkin J. Ipilimumab activity in advanced uveal melanoma. Melanoma Res 2013; 23: 79-81.
22. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 2007; 12: 864-72.
23. Di Giacomo AM, Biagoli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 2010; 37: 499-507.
24. Lebbe C, O'Day S, Chiarion-Sileni V, et al. Analysis of the onset and resolution of immune-related adverse events during treatment with ipilimumab in patients with metastatic melanoma. Perspectives in Melanoma XII 2008; abstr. O-015.
25. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anticytotoxic T-lymphocyte Antigen-4. J Clin Oncol 2005; 23: 6043-53.
26. Lutzky J, Wolchok J, Hamid O, et al. Association between immunerelated adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials. J Clin Oncol 2009; 27: 15s, (suppl; abstr 9034).
27. Di Giacomo AM, Danielli R, Calabr L, et al. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol Immunother 2011; 60: 467-77.